Please assess the completion status of the following clinical trial:

Trial Title: Study to Determine Efficacy & Safety of a Low Concentration Estriol (0.005%) in Postmenopausal Vaginal Atrophy.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Main Inclusion Criteria:~* Women of any age.~* Menopause with amenorrhea time ≥ 2 years, either due to natural or surgical menopause (bilateral oophorectomy).~* Presence of symptoms and signs of atrophy of the vaginal mucosa including at minimum vaginal dryness as a symptom stated by the patient, together with at least one sign of the disease verified by the investigator.~  * As symptoms the patient could state vaginal dryness, pruritus, burning, dyspareunia, dysuria or any other symptom that the investigator considered related to the presence of vaginal atrophy.~ * As signs the investigator assessed in the gynaecological examination with a speculum, a thinned vaginal mucosa or with flattening of folds, a dry, fragile and pale vaginal mucosa, the presence of petechiae or any other sign that the investigator considered indicative of the existence of vaginal atrophy~* Patients with mammography carried out in the period of one year prior to inclusion in the study.~* Patients able to understand the nature and purpose of the study, to cooperate with the investigator and meet the study requirements.~* Patients who gave written informed consent to participate in the study.~Exclusion Criteria:~* Patients with contraindications for hormone therapy with estrogens because they had a history of:~  * Malignant or premalignant lesions of the breasts or endometrium.~ * Pathology of malignant colon tumour.~ * Malignant melanoma~ * Hepatic tumour pathology~ * Venous thromboembolic conditions (deep vein thrombosis, pulmonary embolism) or arterial thromboembolic conditions (angor pectoris, myocardial infarction, cerebrovascular accident), peripheral arterial disease, mesenteric artery thrombosis, renal artery thrombosis~ * Coagulopathies~ * Vaginal bleeding of unknown etiology~* Patients who had abnormal laboratory values at the start of the study that the investigator considered clinically relevant for the purposes of the present study.~* Patients with signs and symptoms suggestive of infection of the genital or urinary tract at the start of the study.~* Patients with any medical-surgical pathology, which was uncontrolled at the time of inclusion in the study.~* Patients with any acute process whose handling or evolution the investigator considered could interfere in the development of the study.~* Patients with endometrial thickness equal to or greater than 4 mm measured by transvaginal ultrasound.~* Patients with grade II or higher uterovaginal prolapse.~* Patients who had received any type of vulvovaginal treatment in the 15 days prior to the start of the study.~* Patients who had received phytoestrogens in the period of one month prior to the start of the study, including administration by vaginal route.~* Patients who had received hormone therapy in the period of 3 months prior to the start of the study, including the administration of estrogens by vaginal route.~* Patients on treatment with drugs described in section 7.3 of the protocol~* Patients with a history of allergy to any of the components of the medication under study (see the composition in section 3.3. of the protocol).~* Patients who had participated in the experimental evaluation of any drug during the 8 weeks before the start of the present study.

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 0.005% Estriol group (Type: EXPERIMENTAL): 0.005% Estriol (50 μg/g) gel for vaginal administration. Route: Vaginal by a cannula inserted deep inside the vagina Single dose: 1 g of gel Dosage schedule: Weeks 1-3: single daily application Weeks 4-12: single application 2 times per week.
- Placebo group (Type: PLACEBO_COMPARATOR): Placebo gel for vaginal administration. Route: Vaginal by a cannula inserted deep inside the vagina Single dose: 1 g of gel Dosage schedule: Weeks 1-3: single daily application Weeks 4-12: single application 2 times per week.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete